Bli medlem
Bli medlem

Du är här


PCI Biotech: Results from the bile duct cancer study will be presented as late-breaking news at United European Gastroenterology Week

Oslo, October 17, 2016 - PCI Biotech today announced that an abstract with
results from the phase I bile duct cancer study has been selected for oral
presentation as late-breaking news at the United European Gastroenterology
(UEG) Week.

The results will be presented by Dr. Alexander Dechêne, University Hospital
Essen, Germany, who is one of the investigators in the phase I study. The
presentation "Phase I study with photochemical Internalisation (PCI) - a
novel technology for treatment of perihilar cholangiocarcinoma" will be held
today at 15:00 local time in room M at the Austria Center Vienna (ACV),
Vienna, Austria. The presentation will be made available on PCI Biotech's
home page.

About United European Gastroenterology (UEG)
United European Gastroenterology, is a professional non-profit organisation
combining all the leading European societies concerned with digestive health.
The member societies represent over 22,000 specialists, working across
medicine, surgery, paediatrics, GI oncology and endoscopy. This makes UEG the
most comprehensive organisation of its kind in the world, and a unique
platform for collaboration and the exchange of knowledge.

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and
commercialisation of novel therapies for the treatment of cancer through its
innovative photochemical internalisation (PCI) technology platform. PCI is
applied to three distinct anticancer paradigms:fimaChem

(enhancement of chemotherapeutics for localised treatment of cancer),fimaVacc

(T-cell induction technology for therapeutic vaccination), andfimaNAc

(nucleic acid therapeutics delivery).

Photochemical internalisation induces triggered endosomal release that is used
to unlock the true potential of a wide array of therapeutic modalities. The
company's leadfimaChem

programme consists of a Phase I/II clinical study in bile duct cancer, an
orphan indication with a high unmet need and without approved

applies a unique mode of action to enhance the essential cytotoxic effect of
therapeutic cancer vaccines, which works in synergy with several other
state-of-the-art vaccination technologies.fimaNAc

utilises the endosomal release to provide intracellular delivery of nucleic
acids, such as mRNA and siRNA therapeutics, thereby addressing one of the
major bottlenecks facing this emerging and promising field.

For more information visit:

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Per Walday, CEO,, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.